Patient Journey in Advanced Gynecologic Cancers
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorTongji Hospital
About this trial
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
Eligibility criteria
Qualifiers
Age 18 or older
Newly diagnosed stage III or IV CC or EC
Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis.
Told by their physician that their disease is stable.
Disqualifiers
Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
Previously participated in or participating in a clinical trial.
Patients who received another line of therapy after initial therapy.
Unable or unwilling to provide informed consent.
Trial design
Treatments tested in this trial
- interview
Treatment groups
780 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov